Company intelligence / Profile preview

S2 Genomics

Livermore, California, United Statess2genomics.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

S2 Genomics commercializes the Singulator platform, an automated benchtop system that prepares single cell and nuclei suspensions from solid tissues. The technology removes bottlenecks in single cell genomics by providing reproducible, rapid, and automated tissue dissociation. It has been adopted globally by academic research organizations, pharmaceutical companies, biotech firms, and service providers since its launch in 2020. No clinical results are relevant as this is a life science tools provider.

Modalities: Device (instrumentation for sample preparation)Reagent (consumables for tissue dissociation)
Industry: Non-Drug Biotech

Partnerships

BonsailabProteigeneTechtum Lab AB

Beyond the preview

Go deeper on S2 Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on S2 Genomics.

Explore the full profile